Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Aug 03, 2026
AMCX: Can the Stock Deliver +38% to Reach $15?

AMCX: Can the Stock Deliver +38% to Reach $15?

Key Takeaways

  • Selected price target: $15 per share, representing roughly 38% upside from the recent trading range near $10.89 and a level the stock last traded above in early 2024.
  • Strongest bullish factors: Deeply discounted valuation with a trailing P/E (price-to-earnings) ratio in the low single digits, robust free cash flow generation exceeding $200 million annually, and a niche streaming portfolio that continues to grow revenue at double-digit rates.
  • Biggest risks: Persistent cord-cutting pressuring linear affiliate revenue, a consensus analyst rating of "Underperform" with average price targets below current levels, and approximately $1.3 billion in net debt weighing on the balance sheet.
  • Key technical levels: Support near $9.40 and resistance around $10.74; a sustained breakout above resistance would be necessary before any credible move toward $15 can begin.
  • Bottom line: While $15 is not an unrealistic long-term aspiration, it would require a significant positive shift in revenue trajectory, successful debt reduction, and a re-rating by Wall Street—conditions that are not yet in place.

The Significance of the $15 Level

The $15 price level carries both psychological and technical significance for AMCX. It sits roughly 38% above where shares recently traded near $10.89 and marks a zone the stock has not sustainably held since early 2024. For a company whose stock traded above $80 as recently as 2015—and above $30 in 2022—the idea of reclaiming $15 may not seem ambitious in historical context. Yet the media landscape has changed dramatically, and investors are now asking whether a return to even this modest threshold is achievable given the structural headwinds facing traditional cable networks.

Company Snapshot

AMC Networks Inc., which now operates under the name AMC Global Media Inc., is a New York-based entertainment company that develops, produces, and distributes content across television and streaming platforms. Its portfolio includes well-known cable networks such as AMC, IFC, SundanceTV, and WE tv, alongside a growing suite of direct-to-consumer streaming services including AMC+, Shudder, Acorn TV, ALLBLK, and Sundance Now. The company is behind major franchises including "The Walking Dead" and the Anne Rice Immortal Universe. Following an international divestiture in late 2023, domestic operations now account for roughly 90% of total revenue. With approximately 1,800 employees and annual revenue around $2.3 billion, AMC Networks remains a mid-sized player navigating the transition from linear television to streaming.

Valuation at a Glance

AMCX presents one of the more striking valuation profiles in the media sector. The stock trades at a trailing P/E ratio of roughly 4.5 and a forward P/E near 3.4, while its price-to-sales ratio sits at approximately 0.18. The company holds roughly $428 million in cash and generated free cash flow of $65 million in the first quarter of 2026 alone, with full-year guidance calling for at least $200 million. These metrics suggest a market that is pricing in substantial earnings erosion rather than stability or growth. The market capitalization of approximately $492 million stands in sharp contrast to annual revenue of about $2.25 billion, reflecting deep skepticism about the company's ability to maintain profitability as linear subscriber losses accelerate. From what I see, this level of discount stands out even in a challenged sector.

Bullish Drivers

Several factors could help AMCX build a case for reaching $15. First, the company's streaming segment has shown genuine momentum, with double-digit year-over-year revenue growth and a 44% increase in digital advertising revenue reported in the first quarter of 2026. Second, management has taken concrete steps to strengthen the balance sheet, retiring 2029 notes and extending roughly 75% of debt maturities into 2032, which reduces near-term refinancing risk. Third, the company's content library—anchored by enduring franchises—continues to generate licensing revenue and provides a foundation for monetization across multiple platforms. Fourth, a recently announced $30 million accelerated share repurchase program signals management's belief that shares are undervalued, and buybacks at current depressed levels could amplify per-share earnings over time. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Potential Roadblocks

The obstacles to reaching $15 are significant. Linear television affiliate revenue declined 16% in the most recent quarter, and that trend shows no sign of reversing as cord-cutting accelerates across the industry. Consolidated adjusted operating income (AOI) dropped 34% year-over-year in the first quarter of 2026, underscoring the profitability squeeze. The company carries approximately $1.3 billion in net debt and finance leases, representing net leverage of about 3.5 times. Meanwhile, competition for streaming subscribers has intensified, with far larger players such as NFLX and DIS commanding resources that AMC Networks cannot match. Finally, institutional ownership declined by over 9% in recent quarters, and the analyst community remains firmly cautious.

Analyst Consensus

Wall Street's current posture toward AMCX is notably cautious. Among the analysts actively covering the stock, the consensus rating is "Underperform" or "Reduce." Wells Fargo raised its price target to $10.00 in February 2026 while maintaining an Equal-Weight rating, making it one of the most optimistic voices on the Street. Morgan Stanley and J.P. Morgan both maintain Underweight ratings with price targets of $6.00 to $7.00. The average 12-month price target across all analysts sits between $7.00 and $8.50—well below the $15 threshold under discussion. Some aggregate forecasts point to a high estimate of $16.00, but these represent the most bullish outlier views rather than consensus expectations. For AMCX to reach $15, a substantial upward revision in analyst estimates would likely need to occur first.

Technical Analysis Perspective

From a technical analysis perspective, AMCX has established a trading range with identifiable boundaries. Support has repeatedly formed near the $9.40 level, with a deeper floor around $8.78 that has held through multiple tests in recent months. On the upside, resistance sits near $10.74, a level that has capped rallies and where the stock has repeatedly failed to sustain momentum. The 200-day moving average, around $8.50 to $9.25 depending on the data source, has recently been reclaimed, which is a modestly positive technical development. However, the stock remains in a longer-term downtrend that traces back to its 2015 all-time high of approximately $87. Any credible move toward $15 would require a decisive breakout above $10.74, followed by clearing the psychological $12.00 level—a zone that aligns with prior breakdown points from early 2024. One thing that stands out here is how the stock has respected these levels repeatedly.

Enhancing Research with AI Tools

In my own process, I often rely on Tickeron's AI Daily Buy/Sell Signals to add an objective layer when reviewing names like AMCX. The platform scans thousands of stocks and ETFs in real time, delivering Buy, Sell, or Hold signals grounded in technical patterns and market data. This helps cut through sentiment and focus on evolving conditions without needing to monitor every chart manually. It has become a practical complement to traditional fundamental work for me when weighing recovery scenarios.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations
Related Ticker: AMCX

Contributor

<p>Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years&nbsp;developing&nbsp;his proprietary trading and quantitative algorithms (now Tickeron&rsquo;s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional,&nbsp;sophisticated stock market analysis capabilities to retail investors via&nbsp;an easy-to-use interface.</p>


Momentum Indicator for AMCX turns positive, indicating new upward trend

AMCX saw its Momentum Indicator move above the 0 level on July 31, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 85 similar instances where the indicator turned positive. In of the 85 cases, the stock moved higher in the following days. The odds of a move higher are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for AMCX just turned positive on July 31, 2026. Looking at past instances where AMCX's MACD turned positive, the stock continued to rise in of 40 cases over the following month. The odds of a continued upward trend are .

AMCX moved above its 50-day moving average on July 31, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where AMCX advanced for three days, in of 278 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 180 cases where AMCX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for AMCX moved out of overbought territory on August 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 23 similar instances where the indicator moved out of overbought territory. In of the 23 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where AMCX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

AMCX broke above its upper Bollinger Band on August 05, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. AMCX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.536) is normal, around the industry mean (20.504). P/E Ratio (11.522) is within average values for comparable stocks, (106.103). Projected Growth (PEG Ratio) (0.545) is also within normal values, averaging (14.111). AMCX has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.016). P/S Ratio (0.264) is also within normal values, averaging (2.942).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AMCX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 77, placing this stock worse than average.

Notable companies

The most notable companies in this group are Netflix Inc. (NASDAQ:NFLX), Walt Disney Company (The) (NYSE:DIS), Roku (NASDAQ:ROKU), Paramount Skydance Corporation (NASDAQ:PSKY), AMC Entertainment Holdings (NYSE:AMC), iQIYI (NASDAQ:IQ), HUYA (NYSE:HUYA).

Industry description

Movies/entertainment industry include companies that produce and distribute motion pictures, and companies that operate general entertainment facilities like amusement parks and bowling centers. Some companies in this industry also have professional sports franchises. Live Nation Entertainment, Inc., Liberty Media Corp. and Viacom Inc. are some of the biggest companies in this space.

Market Cap

The average market capitalization across the Movies/Entertainment Industry is 17.01B. The market cap for tickers in the group ranges from 134 to 306.84B. NFLX holds the highest valuation in this group at 306.84B. The lowest valued company is LRDG at 134.

High and low price notable news

The average weekly price growth across all stocks in the Movies/Entertainment Industry was -1%. For the same Industry, the average monthly price growth was 1%, and the average quarterly price growth was 8%. AMCX experienced the highest price growth at 22%, while KWM experienced the biggest fall at -96%.

Volume

The average weekly volume growth across all stocks in the Movies/Entertainment Industry was -24%. For the same stocks of the Industry, the average monthly volume growth was -20% and the average quarterly volume growth was -53%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 64
P/E Growth Rating: 53
Price Growth Rating: 55
SMR Rating: 84
Profit Risk Rating: 76
Seasonality Score: -17 (-100 ... +100)
View a ticker or compare two or three
AMCX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

an operator of cable television networks through its subsidiaries

Industry MoviesEntertainment

Profile
Details
Industry
Cable Or Satellite TV
Address
11 Penn Plaza
Phone
N/A
Employees
1738
Web
https://www.amcglobalmedia.com
Interact to see
Advertisement
Novartis (NVS) reports Q4/FY 2025 earnings on February 4, 2026, with consensus calling for ~$1.99 EPS on ~$13.7 billion in revenue. Sanofi (SNY) delivered strong FY 2025 results on January 29, reporting €43.6 billion in sales (+9.9% CER) and 15% business EPS growth.
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
MUFG is expected to report Q3 FY2026 EPS of about $0.30, broadly in line with its recent pattern of earnings beats.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
CME Group (CME): Q4 2025 earnings due February 4, 2026; consensus expects adjusted EPS $2.75 and revenue ~$1.6B. S&P Global (SPGI): Q4 2025 earnings due February 10, 2026; Q3 posted EPS $4.73 and 9% revenue growth, driven by Ratings, Indices, and Market Intelligence.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.